Empagliflozin in Hypertrophic Cardiomyopathy

Inclusion Criteria: * written, voluntary informed consent to participate in the study * diagnosis of hypertrophic cardiomyopathy * age ≥ 18 years Exclusion Criteria: * refusal to consent to participate in the study * diagnosis of diabetes * patients with hypertrophic obstructive cardiomyopathy requiring interventional treatment (maximal LVOT gradient ≥ 50 mmHg), and who are in III-IV NYHA functional class, despite of the treatment with maximal tolerated doses * refusal to consent to participate in the study * diagnosis of diabetes * patients with hypertrophic obstructive cardiomyopathy requiring interventional treatment (maximal LVOT gradient ≥ 50 mmHg), and who are in III-IV NYHA functional class, despite of the treatment with maximal tolerated doses * ICD or cardiac pacemaker (for a group of patients in whom cardiac magnetic resonance study will be performed; n=100) * planned implantation of cardiac resynchronization therapy (CRT of CRT-D) in the following 12 months * life expectancy below 12 months * pregnancy (currently or planned in the following 12 months) * breast feeding * age below 18 years * recurrent genito-urinary tract infections in the past or currently * urosepsis in the history * Impaired renal function, defined as eGFR \< 30 mL/min/1.73 m2 (CKD-EPI)cr or requiring dialysis, * other contraindications to the use of empagliflozin * musculo-skeletal or neurologic diseases that make it unable to perform cardiopulmonary exercise testing * heart transplant recipi…